Logo.jpg
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
23 juil. 2021 04h15 HE | Biofrontera AG
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für...
Logo.jpg
Biofrontera Inc. seeks IPO in the USA
06 juil. 2021 17h59 HE | Biofrontera AG
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc. Biofrontera AG had already announced that opportunities...
Logo.jpg
Biofrontera reports preliminary revenue for the month of June 2021
06 juil. 2021 10h00 HE | Biofrontera AG
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Logo.jpg
Biofrontera provides update on clinical developments
22 juin 2021 09h00 HE | Biofrontera AG
Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
Logo.jpg
Biofrontera reports preliminary revenue for the month of May 2021
07 juin 2021 10h01 HE | Biofrontera AG
Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Logo.jpg
Biofrontera AG: First quarter conference call to be held on May 12, 2021
03 mai 2021 09h40 HE | Biofrontera AG
Leverkusen, Germany, May 03, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its ...
Logo.jpg
Biofrontera reports results for the 2020 financial year
12 avr. 2021 13h57 HE | Biofrontera AG
Leverkusen, Germany, April 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Logo.jpg
Biofrontera announces preliminary revenue for Q1 2021
08 avr. 2021 10h30 HE | Biofrontera AG
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Logo.jpg
Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
31 mars 2021 03h40 HE | Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Logo.jpg
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
26 févr. 2021 09h20 HE | Biofrontera AG
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...